Q-omics provides the consensus-scored EXOSC10 profile across patient tissues and cancer cell-line models. EXOSC10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EXOSC10 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, EXOSC10 protein abundance shows 24,132 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where EXOSC10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXOSC10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXOSC10 survival associations across molecular data types. EXOSC10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXOSC10 RNA expression–survival associations across cancer types. High EXOSC10 expression shows unfavorable associations in ACC, LGG, LIHC and LUSC, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EXOSC10 RNA expression.
This table summarizes EXOSC10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EXOSC10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXOSC10 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LIHC, LUAD and STAD. The BLCA box plot shows higher EXOSC10 RNA expression in tumor versus normal tissue (log2 FC = +0.742, t-test p < 0.001).
This table shows molecular features associated with EXOSC10 in patient tissues and cancer cell lines. In patient samples, EXOSC10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EXOSC10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
